Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 20/20 | 1.00 |
| ▸ | PDE6C | P51160 | 2/20 | 0.65 |
| ▸ | PDE11A | Q9HCR9 | 1/20 | 0.65 |
| ▸ | PDE6D | O43924 | 1/20 | 0.63 |
| ▸ | PDE6A | P16499 | 1/20 | 0.63 |
| ▸ | PDE6G | P18545 | 1/20 | 0.63 |
| ▸ | PDE6B | P35913 | 1/20 | 0.63 |
| ▸ | PDE6H | Q13956 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7407534 | 0.96 | PDE5A (0.92) | PDE5APDE6CPDE11A | |
| SCHEMBL7409850 | 0.94 | PDE5A (0.88) | PDE5APDE6CPDE11APDE6DPDE6A | |
| SCHEMBL7517766 | 0.93 | PDE5A (0.87) | PDE5APDE6CPDE11A | |
| SCHEMBL7409432 | 0.92 | PDE5A (0.85) | PDE5APDE6CPDE11A | |
| SCHEMBL7410568 | 0.92 | PDE5A (0.84) | PDE5APDE6CPDE11A | |
| SCHEMBL7407315 | 0.91 | PDE5A (0.83) | PDE5APDE6CPDE11A | |
| SCHEMBL7414701 | 0.89 | PDE5A (0.80) | PDE5A | |
| SCHEMBL8207075 | 0.88 | PDE5A (0.78) | PDE5APDE6CPDE11A | |
| SCHEMBL7409410 | 0.88 | PDE5A (0.77) | PDE5APDE6CPDE11APDE6DPDE6A | |
| SCHEMBL8206824 | 0.88 | PDE5A (0.78) | PDE5APDE6CPDE11A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100179152-A1 | Novel use for PDE5 inhibitors | NYCOMED GMBH (DE) | 2010-07-15 | — | — | US | claimed |
| EP-1740183-B1 | NOVEL USE FOR PDE5 INHIBITORS | NYCOMED GMBH (DE) | 2009-10-14 | — | — | EP | claimed |
| US-20070185114-A1 | Novel use for pde5 inhibitors | ALTANA PHARMA AG (DE) | 2007-08-09 | — | — | US | claimed |
| JP-2006528229-A | — | — | 2006-12-14 | — | — | JP | claimed |
| US-20060148693-A1 | Composition comprising a pulmonary surfactant and a pde5 inhibitor for the treatment of lung diseases | ALTANA PHARMA AG (DE) | 2006-07-06 | — | — | US | claimed |
| US-20060094723-A1 | Composition comprising a pde4 inhibitor and a pde5 inhibitor | NYCOMED GMBH (DE) | 2006-05-04 | — | — | US | claimed |
| EP-1638567-A1 | COMPOSITION COMPRISING A PULMONARY SURFACTANT AND A PDE5 INHIBITOR FOR THE TREATMENT OF LUNG DISEASES | ALTANA Pharma AG (DE) | 2006-03-29 | — | — | EP | claimed |
| EP-1628682-A2 | COMPOSITION COMPRISING A PDE4 INHIBITOR AND A PDE5 INHIBITOR | ALTANA Pharma AG (DE) | 2006-03-01 | — | — | EP | claimed |
| WO-2004110450-A1 | COMPOSITION COMPRISING A PULMONARY SURFACTANT AND A PDE5 INHIBITOR FOR THE TREATMENT OF LUNG DISEASES | ALTANA PHARMA AG (DE) | 2004-12-23 | — | — | WO | claimed |
| WO-2004103407-A2 | COMPOSITION COMPRISING A PDE4 INHIBITOR AND A PDE5 INHIBITOR | ALTANA PHARMA AG (DE) | 2004-12-02 | — | — | WO | claimed |
| EP-1461022-A2 | USE OF SELECTIVE PDE5 INHIBITORS FOR TREATING PARTIAL AND GLOBAL RESPIRATORY FAILURE | ALTANA Pharma AG (DE) | 2004-09-29 | — | — | EP | claimed |
| WO-2003051346-A2 | USE OF SELECTIVE PDE5 INHIBITORS FOR TREATING PARTIAL AND GLOBAL RESPIRATORY FAILURE | ALTANA PHARMA AG (DE) | 2003-06-26 | — | — | WO | claimed |
| US-6087368-A | AN ENZYME INHIBITOR TREATING ERECTILE DYSFUNCTION OF SEX DISORDERS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2000-07-11 | — | — | US | claimed |
| EP-0760683-B1 | BILE ACID CONJUGATES, DERIVATIVES THEREOF WITH METAL COMPLEXES AND RELATED USES | BRACCO SPA (IT) | 2000-01-05 | — | — | EP | claimed |
| EP-3267986-B1 | PDE5 INHIBITORS FOR USE IN REDUCING RENAL CYST SIZE AND/OR PREVENTING RENAL CYST GROWTH | UNIV INDIANA RES & TECH CORP (US) | 2022-09-14 | — | — | EP | disclosed |
| CN-107847462-B | Targeting cGMP-related phosphodiesterases to reduce cyst formation of cystic kidney disease and related materials and methods | 美国印第安纳大学研究和技术公司 | 2021-08-10 | — | — | CN | disclosed |
| US-10456404-B2 | Targeting cGMP-related phosphodiesterases to reduce cyst formation in cystic kidney disease, and related materials and methods | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2019-10-29 | — | — | US | disclosed |
| EP-1461022-A2 | USE OF SELECTIVE PDE5 INHIBITORS FOR TREATING PARTIAL AND GLOBAL RESPIRATORY FAILURE | ALTANA Pharma AG (DE) | 2004-09-29 | — | — | EP | disclosed |
| WO-2003051346-A2 | USE OF SELECTIVE PDE5 INHIBITORS FOR TREATING PARTIAL AND GLOBAL RESPIRATORY FAILURE | ALTANA PHARMA AG (DE) | 2003-06-26 | — | — | WO | disclosed |
| US-6087368-A | AN ENZYME INHIBITOR TREATING ERECTILE DYSFUNCTION OF SEX DISORDERS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2000-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094723-A1 | Composition comprising a pde4 inhibitor and a pde5 inhibitor | PDE5A, PDE12, PDE4A | PDE5A 1/4885PDE6C 20/4885PDE11A 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.